高特异性和细胞毒性三阴性乳腺癌的分子工程三化物
Jiaxuan He1, Tianhuan Peng1, Yongbo Peng1
1Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province , Hunan University , Changsha 410082 , People's Republic of China.
Journal of the American Chemical Society
|January 8, 2020
概括
一种新型的阿普塔默-药物结合物,AS1411-三结合物 (ATC),在治疗三阴性乳腺癌 (TNBC) 方面表现出高的疗效和特异性. 这种向疗法在体内表现出优异的抗TNBC效果,副作用极小.
科学领域:
- 生物医学
- 癌症学
- 药物开发
背景情况:
- 三重阴性乳腺癌 (TNBC) 是一种缺乏ER,PR和HER2受体的侵袭性亚型,导致复发率更高.
- 开发有针对性的疗法对于改善TNBC治疗结果至关重要.
- 目前TNBC的治疗选择有限,需要新的治疗策略.
研究的目的:
- 开发和评估用于向性TNBC治疗的新型合剂 (ApDC).
- 评估AS1411-三类结合剂 (ATC) 对TNBC的疗效和特异性.
- 调查ATC的体内性能和安全性.
主要方法:
- 合成和表征AS1411-三类结合物 (ATC).
- 使用MDA-MB-231TNBC细胞系进行体外细胞毒性测定.
- 在相关模型中评估抗瘤功效和评估副作用的体内研究.
主要成果:
- 开发的ATC对MDA-MB-231TNBC细胞系具有很高的特异性和强大的细胞毒性.
- 在体内研究表明,ATC在对抗TNBC方面具有很好的疗效.
- ATC对健康器官的副作用是可以忽略的,这表明安全性很好.
结论:
- 这种新型的阿普坦-药物结合物ATC是三阴性乳腺癌的有希望的向治疗方法.
- ATC 具有很高的疗效和特异性,为TNBC提供了潜在的新治疗途径.
- 良好的体内特征表明ATC可能是TNBC患者的安全和有效治疗选择.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.5K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K


